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Background: This study aimed to measure the serum soluble tumor necrosis factor-like weak inducer of apoptosis
(sTWEAK) and interleukin-17A (IL-17A) levels in hypertensive patients with/without asymptomatic organ damage
(AOD), as well as to determine the relationship between the serum sTWEAK and IL17-A levels, and carotid intima
media thickness (CIMT), proteinuria, retinopathy, and the left ventricle mass index (LVMI).
Methods: The study included 159 patients diagnosed with and followed-up for primary hypertension (HT); 79 of
the patients had AOD (61 female and 18 male) and 80 did not (52 female and 28 male). sTWEAK and IL-17A levels
were measured in all patients.
Results: The sTWEAK level was significantly lower in the patients with AOD than in those without AOD (858.4 pg/mL
vs. 1151.58 pg/mL, P = 0.001). The sTWEAK level was negatively correlated with the mean microalbuminuria level and
LVMI. The median IL-17A level was significantly higher in the patients with AOD than in those without AOD (2.34 pg/
mL vs. 1.80 pg/mL, P = 0.001). There was a positive correlation between mean IL-17A level, and mean microalbuminuria
level, CIMT, and LVMI. Multivariate logistic regression analysis showed that patient age, sTWEAK level, and mean 24-h
systolic blood pressure were predictors of AOD.
Conclusions: The sTWEAK level was lower and IL-17A level was higher in the patients with AOD. It remains
unknown if sTWEAK and IL-17A play a role in the pathophysiology of AOD. Prospective observational studies are
needed to determine the precise role of sTWEAK and IL-17A in the development of target organ damage.
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apoptosisBackground
Hypertension (HT) is a major risk factor for cardiovascular
events (e.g. stroke, heart attack, sudden death, heart failure,
and peripheral artery disease) and end-stage renal disease
[1]. In addition to accelerated atherosclerosis, HT causes
organ damage, including left ventricle hypertrophy, renal
dysfunction, arterial aneurysm, and retinopathy, resulting* Correspondence: dr.ihsanates@hotmail.com
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ease, its etiopathogenesis remains largely unknown. While
historically an emphasis has been placed on the role of salt
intake, obesity, insulin resistance, the renin-angiotensin
system, and the sympathetic nervous system in the etio-
pathogenesis of HT [2], endothelial dysfunction and im-
mune mechanisms have recently become the focus of
greater attention [3]. In addition, recent studies have exam-
ined the association between HT, and T lymphocytes and
cytokines [4-7].d. This is an Open Access article distributed under the terms of the Creative
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(TWEAK) is a member of the tumor necrosis factor
(TNF) superfamily that was first described in 1997 [8].
As other members of the TNF superfamily, TWEAK
has multiple forms: mTWEAK, which is bonded to the
membrane, and sTWEAK, which is a soluble variant
produced following proteolytic cleavage by endoprotease
furin. Both of these forms are biologically active [9].
sTWEAK binds to fibroblast growth factor-inducible
molecule 14 (Fn14) receptors, and plays a role in cellular
proliferation, migration, apoptosis, differentiation, angio-
genesis, and inflammation via the nuclear factor κB (NF-
κB) pathway [10].
In 2005 interleukin-17 (IL-17) was known as a cytokine
produced only by T helper 17 [11], but more recent stud-
ies have shown that it can be produced by macrophages,
dendritic cells, natural killer cells, natural killer T cells, and
γδ T cells. There are 6 known types of IL-17 (IL-17A-F);
the prototype is IL-17A [5]. IL-17A is known to play a role
in autoimmune and inflammatory diseases, including
rheumatoid arthritis, psoriasis, multiple sclerosis, asthma,
and inflammatory bowel disease [12,13], and in chronic
vascular inflammation, atherosclerosis, and hypertensive
vascular changes [14]. The literature does include studies
on sTWEAK and IL-17A in patients with HT [4,5,7], but
does not include any studies on the relationship between
sTWEAK and IL-17A, and asymptomatic organ damage
(AOD) in HT patient.
As such, the present study aimed to measure serum
levels of sTWEAK and of IL-17A in patients with pri-
mary HT -with/without AOD- as well as to determine
the relationship between the serum sTWEAK and IL17-
A levels, and such markers of AOD as carotid intima
media thickness (CIMT), proteinuria, retinopathy, and
the left ventricular mass index (LVMI).
Methods
This study was conducted at the Ankara Numune Educa-
tion and Research Hospital, Nephrology Clinic, Ankara,
Turkey, between July 2013 and November 2013. The study
was performed in accordance with the Declaration of
Helsinki and the study protocol was approved by the
Ankara Numune Education and Research Hospital Ethics
Committee. All the patients provided written informed
consent to participate in the study.
The study included 159 patients aged >18 years that were
previously diagnosed as HT; 79 patients with AOD (18
male and 61 female) (based on grade III-IV retinopathy,
LVMI >95 g/m2 for females and >115 g/m2 for males,
CIMT >0.9 mm or plaque, microalbuminuria (30–300 mg/
24-h) and 80 patients without AOD (28 male and 52
female). Patients with secondary HT, dyslipidemia (low-
density lipoprotein [LDL] cholesterol >130 mg/dL, triglyc-
erides [TG] >150 g/dL), diabetes mellitus, acute renalinjury, nephrotic proteinuria, coronary heart disease, heart
failure, peripheral artery disease, cerebrovascular events,
malignancy, liver disease, rheumatic diseases, thyroid dis-
eases, and cigarette and alcohol use were excluded.
Duration of HT (years) was calculated based on pa-
tient self-reports of the date they were first diagnosed as
HT to the date of inclusion in the study. The types of
antihypertensive drugs the patients used included renin
angiotensin system (RAS) blockers, calcium channel
blockers (CCB), beta blockers, and diuretics.
The WatchBP 03 device (Microlife WatchBP AG,
Switzerland) was used for 24-h ambulatory blood pres-
sure monitoring (ABPM). Patients were informed about
the procedure and the device; they were instructed to
perform their daily activities as normal, but to remain
immobile while the device was recording measurements.
The devices were programmed to record blood pressure
measurements every 15 min from 07.00 to 23.00 (day-
time) and every 20 min from 23.00 to 07.00 (nighttime).
The method was considered reliable if >70% of measure-
ments were valid.
Biochemical parameters
Blood samples for analysis of biochemical parameters
were collected in the morning following a 12-h fasting.
Collected blood was immediately centrifuged at 4000 rpm
for 10 min to separate the plasma and serum, and serum
was stored at −80°C until analyzed. All biochemical
parameters were analyzed in the same serum sample.
Patients were asked to collect 24-h urine samples; they
were instructed not to collect urine from the first urin-
ation after waking the morning of the day they started to
collect the urine, to urinate into a collection container
during every urination thereafter, including the first urin-
ation upon waking the following morning, and to bring all
the collected urine to the laboratory.
Photometric analysis of hemoglobin was performed
using a Sysmex XE 2100 (Roche Diagnostics Corp. Indi-
ana, USA) hematology auto-analyzer, 24-h urine protein
was measured via the microalbumin turbidimetric
method, creatinine and total protein were measured
using the albumin colorimetric method, uric acid, fasting
glucose, TG and total cholesterol were measured via
the enzymatic colorimetric method, and high-density
lipoprotein (HDL) cholesterol was measured via the
homogenous enzymatic colorimetric method using a
Hitachi Modular P800 (Roche Diagnostics Corp. Indi-
ana, USA) auto-analyzer. LDL cholesterol was calculated
using the Friedewald method [15]. The GFR (glomerular
filtration rate) was calculated according to the simplified
version of the Modification of Diet in Renal Disease Study
prediction equation formula, as follows: GFR = 186 ×
creatinine– 1.154 × age– 0.203 × 1.212 (if African ‐American) ×
0.742 (if female) [16].
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Serum sTWEAK (pg/mL) was measured using a serum
ELISA kit (eBioscience, Human TWEAK Instant ELISA,
cat. no. BMS2006INST). The calculated overall intra-assay
and inter-assay coefficients of variation were 7.9-9.2%.
IL-17A measurement
Serum IL-17A (pg/mL) was measured using a serum ELISA
kit (eBioscience, human IL-17A platinum ELISA, cat. no.
BMS2017). The calculated overall intra-assay and inter-
assay coefficients of variation were 7.1-9.1%.
Fundoscopic examination
Into both eyes of each patient, 1 drop of tropicamide 1%
solution was administrated 15 min prior to funduscopic
examination. Funduscopic examination was performed
using a biomicroscopy device (Topcon SL-3C, Topcon
Corporation, Japan). Retinopathy staging was performed
in accordance with ESC/ESH 2013 hypertension guide-
lines, as follows: grade I: focal or general arteriolar nar-
rowing; grade II: arteriovenous nicking; grade III: retinal
hemorrhages, microaneurysms, hard exudates, and cot-
ton wool spots; grade IV: grade III signs and papilledema
and/or macular edema) [1].
Echocardiographic examination
Echocardiography was performed by an investigator blinded
to each patient’s clinical status, using a commercial echocardi-
ography machine (Vivid 7, GE Vinged Ultrasound AS,
Horten, Norway) equipped with a 2.5-MHz phased array
transducer. Complete 2D, color, pulsed, and continuous-wave
Doppler examinations were performed according to standard
techniques. The LVMI was calculated from 2D echocardio-
graphic measurements, using the Devereux formula, and
was indexed to body surface area, as follows: LVMI = 1.04 ×
[(IVST + PWT + LVDd)3 – (LVDd)3] – 13.6 [17].
Carotid ultrasonography
CIMT was measured with patients in the supine position
with their hand bent backwards. One radiologist that was
blinded to the clinical status of the patients used a high-
resolution B-mode ultrasound device (Logic 7, GE Med.
Inc., USA), a linear probe on the right and left common ca-
rotid artery, and an automated system. Measurements were
made at 3 points: the right and left common carotid artery,
bifurcation, and first 2 cm of the internal carotid artery.
Longitudinal measurements were made from the distances
defined as vessel lumen echogenicity and media-adventitia
echogenicity. Mean CIMT was calculated by averaging 3
measurements made at each carotid artery [18].
Statistical analysis
Statistical analysis were performed using Statistical Pack-
age for Social Sciences (SPSS) v.20.0 for Windows (SPSS,Inc., Chicago, IL). Kolmogorov-Smirnov test was used to
analyze data with normal distribution. Numeric parame-
ters with normal distribution are presented as mean ±
standard deviation (SD) and numeric parameters without
normal distribution are presented as median. Categorical
variables are expressed as number and percentage. Corre-
lations between numeric parameters were analyzed via
Pearson’s and Spearman’s correlation analysis. The chi-
square test and Fisher’s exact chi-square test were used to
compare categorical variables. Between-group differences
in numeric parameters with normal distribution were ana-
lyzed using the independent samples t test, and between-
group differences in numeric parameters without normal
distribution were analyzed using the Mann–Whitney U
test. The effect of risk factors associated with AOD alone
was analyzed via univariate logistic regression analysis.
Significant variables based on logistic regression analysis
were incorporated into a multivariate logistic regression
model. ROC (receiver operating characteristic) curve ana-
lysis was used to determine the value of the serum
sTWEAK level in predicting AOD. To determine the
prediction point the point with the highest sensitivity
and specificity, and the lowest false positive and false
negative predictive points were selected. The level of
statistical significance was set at P < 0.05
Results
The study included 159 patients; 79 patients with AOD
(18 male and 61 female; mean age: 54.7 ± 12.0 years) and
80 patients without AOD (28 male and 52 female; mean
age: 49.4 ± 11.5 years). There weren’t any significant differ-
ences in demographic data between the 2 groups, except
for mean age and median duration of HT (P < 0.05). Pa-
tients in both groups used RAS blockers, CCBs, beta
blockers, and diuretics as antihypertensive drugs. Al-
though mean 24-h systolic blood pressure (SBP) and 24-h
diastolic blood pressure (DBP) were significantly higher in
the AOD group, there weren’t any significant differences
between groups according to the type of antihypertensive
drugs used (P > 0.05). Demographic and laboratory find-
ings in both groups are presented in Table 1.
In evaluation of all patients for types of antihyperten-
sive drugs used, means of 24 –h SBP and 24-h DBP for
patients received RAS blocker, CCB, beta blocker and di-
uretics were similar (P > 0.05).
Mean 24-h SBP and 24-h DBP were significantly higher
in the AOD group (24-h SBP: 129.5 mmHg ± 16.8 mmHg
vs. 119.2 mmHg ± 9.9 mmHg, P = 0.001; 24-h DBP:
79.5 mmHg ± 11.8 mmHg vs. 76.1 mmHg ± 6.9 mmHg,
P = 0.029). Median serum sTWEAK was significantly
lower in the AOD group (858.4 pg/mL vs. 1151.58 pg/mL,
P = 0.001) (Figure 1). Median IL-17A was significantly
higher in the AOD group (2.34 pg/mL vs. 1.80 pg/mL,
P = 0.001) (Figure 2).
Table 1 Patient demographic and laboratory findings
Variables All patients Patients with AOD Patients without AOD P
n (%) 159 79 (49.6%) 80 (50.4%)
Age (years) 52.02 ± 12.1 54.71 ± 12.0 49.36 ± 11.5 0.005*
Gender 0.115
Female, n (%) 113 (71.1) 61 (77.2) 52 (65)
Male, n (%) 46 (28.9) 18 (22.8) 28 (35)
BMI (kg/m2) 29.55 ± 4.7 30.04 ± 4.7 29.05 ± 4.6 0.195
Duration of HT (years) 3.74 (4) 5 (3) 2.5 (4) 0.037*
Antihypertensive drugs
Class (n,%)
RAS blocker 86 (54.1) 45 (57.0) 41 (51.2) 0.470
Beta blocker 28 (17.6) 17 (21.5) 11 (13.8) 0.198
CCB 63 (39.6) 35 (44.3) 28 (35.0) 0.230
Diuretic 54 (34) 26 (33.8) 28 (36.8) 0.691
CIMT (mm) 0.75 ± 0.17 0.80 ± 0.2 0.68 ± 0.1 0.001*
LVMI (g/m2) 90.05 ± 21.1 100.57 ± 21.1 78.64 ± 13.9 0.001*
Microalbuminuria (mg/d) 10 (15,8) 19.32 (41,7) 7.17 (6,9) 0.001*
Proteinuria (mg/d) 94.98 (70.4) 111.25 (114.8) 84.25 (59.1) 0.001*
Retinopathy (n,%) 0.002*
None 91 (57.2) 39 (49.4) 52 (65.0)
Grade I 28 (17.6) 13 (16.5) 15 (24.6)
Grade II 28 (17.6) 15 (19.0) 13 (21.3)
Grade III 12 (7.5) 12 (15.2) -
sTWEAK (pg/mL) 961.12 (560.9) 858.4 (365.2) 1151.58 (598.4) 0.001*
IL-17A (pg/mL) 2.1 (0,9) 2.34 (0,9) 1.80 (0,7) 0.001*
24-h SBP (mmHg) 124.31 ± 14.7 129.53 ± 16.8 119.16 ± 9.9 0.001*
24-h DBP (mmHg) 77.83 ± 9.8 79.53 ± 11.8 76.15 ± 6.9 0.029*
Numeric parameters are shown as mean ± SD and median (interquartile range).
Categorical parameters are shown as n (%).
*Denotes a significant difference between the groups (P < 0.05).
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with the microalbuminuria level, proteinuria level, LVMI,
mean 24-h SBP, and duration of HT (P < 0.05); however,
the serum sTWEAK level was not correlated with CIMT,
retinopathy stage, or mean 24-h DBP (P > 0.05). There
was a weak negative correlation between the serum
sTWEAK level and patient age (r = −0.183, P = 0.021).
There was a positive correlation between the IL-17A
level, and the microalbuminuria level, proteinuria level,
CIMT, LVMI, and mean 24-h SBP (P < 0.05); however,
retinopathy stage and mean 24-h DPB were no corre-
lated with the IL-17A level (P > 0.05). There was a weak
positive correlation between the IL-17A level and patient
age (r = 0.184, P = 0.020, and a moderately negative cor-
relation between the serum sTWEAK level and IL-17A
level (r = −0.354, P < 0.05).
Mean age of HT patients with AOD was significantly
higher than of those without AOD (54.71 ± 12.0 vs49.36 ± 11.5; p = 0.005). The age factor was also included
in the regression model and thus it is determined that
decreased sTWEAK level independent of age increased
the risk for AOD (OR = 0.985, p = 0.002).
Mean 24-h SBP was positively correlated with the
microalbuminuria level, proteinuria level, CIMT, and
LVMI (P < 0.05); however, retinopathy stage and mean
24-h SBP were not correlated (P > 0.05). In addition,
there wasn’t a correlation between mean 24-h SBP and
patient age (r = −0.027, P = 0.733). There was a positive
correlation between mean 24-h DBP, and the microalbu-
minuria level and CIMT (P < 0.05); however, retinopathy
stage was not correlated with proteinuria or LVMI (P >
0.05). Table 2 shows the correlation analyses in detail.
Retinopathy stage ≥ III, microalbuminuria, proteinuria,
LVMI, and CIMT findings were not included in the lo-
gistic regression analysis, as they were used to identify
target organ damage.
Figure 1 Between-group comparison of the serum sTWEAK level.
Figure 2 Between-group comparison of the serum IL-17A level.
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Table 2 Correlation analysis of sTWEAK, IL-17A, 24-h SBP, and 24-h DBP, and the risk factors
Variables sTweak IL17-A 24-h SBP 24-h DBP
r P r P r P r P
Microalbuminuria −0.188 0.024* 0.253 0.002* 0.430 0.001* 0.241 0.004*
Proteinuria −0.165 0.048* 0.193 0.023* 0.195 0.019* 0.144 0.084
CIMT −0.104 0.340 0.229 0.036* 0.366 0.001* 0.217 0.043*
LVMI −0.264 0.001* 0.327 0.001* 0.283 0.001* 0.143 0.082
Retinopathy Grade −0.137 0.130 0.120 0.193 0.079 0.387 −0.021 0.815
24-h SBP −0.186 0.019* 0.300 0.001* - - 0.769 0.001*
24-h DBP −0.057 0.475 0.146 0.070 0.769 0.001* - -
sTWEAK - - −0.354 0.001* −0.186 0.019* −0.057 0.475
IL-17A −0.354 0.001* - - 0.300 0.001* 0.146 0.070
Duration of HT −0.159 0.045* 0.117 0.144 0.050 0.532 −0.121 0.130
Age −0.183 0.021* 0.184 0.020* −0.027 0.733 −0.252 0.001*
*Denotes a significant correlation (P < 0.05).
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17A, 24-h SBP, and 24-h DBP were associated with
AOD and were analyzed via univariate logistic regres-
sion, and the significant risk factors were included in the
multivariate logistic regression model. Multivariate logis-
tic regression analysis showed that patient age (OR =
1.045, P = 0.012), the sTWEAK level (OR = 0.985, P =
0.002), and mean 24-h SBP (OR = 1.065, P = 0.001) were
predictive of AOD (Table 3). A serum sTWEAK level ≤
877.78 pg/mL predicted AOD with sensitivity of 58.23%
and specificity of 78.75% (AUC = 0.706 ± 0.041 (SE); 95%
CI: 0.629-0.775; P < 0.001) (Figure 3). Age >59 years pre-
dicted AOD with sensitivity of 45.24% and specificity of
76.25% (AUC = 0.590 ± 0.045(SE); 95% CI: 0.519-0.670;
P = 0.027). A mean 24-h SBP level >127 mmHg pre-
dicted AOD with sensitivity of 49.38% and specificity of
73.75% (AUC = 0.603 ± 0.042(SE); 95% CI: 0.524-0.682;
P = 0.003). The AUC value for the sTWEAK level pre-
dictive of AOD was higher than that for age and 24-h
SBP (24-h SBP vs. sTWEAK: AUC: 0.103, P = 0.033; SBP
vs. age: AUC: 0.013, P = 0.806; sTWEAK vs. age: AUC:
0.116, P = 0.028). The present findings indicate that theTable 3 Logistic regression analysis of the risk factors
associated with AOD
Variables Univariate Multivariate
OR (95% CI) P OR (95% CI) P
Age 1.040 (1.011-1.070) 0.006* 1.045 (1.010-1.076) 0.012*
Duration of HT 1.062 (1.046-1.143) 0.042* 0.995 (0.911-1.087) 0.236
sTWEAK 0.990 (0.985-0.994) 0.001* 0.985 (0.983-0.996) 0.002*
IL-17A 1.138 (1.030-1.393) 0.021* 0.996 (0.805-1.232) 0.495
24-h SBP 1.061 (1.032-1.091) 0.001* 1.065 (1.030-1.093) 0.001*
24-h DBP 1.038 (1.020-1.075) 0.034* 0.943 (0.875-1.017) 0.125
Nagelkerke R2 = 0.343, P < 0.05.
*P < 0.05 is considered significant for statistical analyses.serum sTWEAK level was a better diagnostic predictor
of AOD than patient age and mean 24-h SBP.
Discussion
In the present study the serum sTWEAK level was signifi-
cantly lower and the IL-17A level was significantly higher
in the HT patients with AOD than in those without AOD.
To the best of our knowledge the present study is the
first to investigate the relationship between AOD in HT
patients, and the serum sTWEAK and IL-17A levels.
Recent studies indicate that HT and AOD associated
with HT not only occur due to hemodynamic distur-
bances, but that the natural and adaptive immune sys-
tems play a role [19]. Several rat studies reported that
following infusion of deoxycorticosterone acetate and
angiotensin II, a number of cytokines (TNF-a, IL-1B, IL-
6, IL-10, IL-17, and TGF-B1) were synthesized by the
natural and adaptive immune systems, resulting in vas-
cular inflammation [5,20]. Although many cytokines are
known to play a role in the etiopathogenesis of HT, the
relationship between HT, and IL-17A and sTWEAK re-
mains unclear.
TWEAK is a cytokine of the TNF family that activates
many components of cellular activity, including cell
reproduction and cell death [20]. Some studies that in-
vestigated the sTWEAK level reported that it was low in
patients with acute coronary syndrome [21], heart failure
[22], coronary artery disease [23], chronic renal disease
[24], and kidney transplantation [25]. Various explana-
tions for low sTWEAK levels in such patients have been
posited, including that in cases of chronic inflammation
the Fn14 level increases and binds to sTWEAK, result-
ing in a decrease in the serum sTWEAK level [26], and
that an increase in the scavenger receptor CD 163 level
causes inflammatory macrophages to break down
sTWEAK in the presence of inflammation [27].
Figure 3 ROC curve analysis of the prediction of AOD based on the serum sTWEAK level.
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et al.’s [7] study is the only one to have examined the re-
lationship between the serum sTWEAK level and HT.
Their study included 51 patients that were recently diag-
nosed as HT and treatment naïve; the mean sTWEAK
level in the HT patients was lower than that in the
healthy control group, but the relationship between the
sTWEAK level and AOD was not investigated. In the
present study the serum sTWEAK level was observed to
be lower in the HT patients AOD than in those without
AOD. Sustained high blood pressure can lead to chronic
inflammation, resulting in target organ damage, such as
atherosclerosis and proteinuria. The lower sTWEAK
level in the present study’s HT patients with AOD might
have been due to chronic inflammation that already
existed.
An earlier study reported that high levels of Fn14 in
patients with cardiac hypertrophy was associated with el-
evated blood pressure and that the sTWEAK level was
lower in the cardiac hypertrophy patients because of
binding to Fn14 receptor [28]. Another study reported
elevated Fn14 levels in patients with non-immune pri-
mary glomerular disease and proteinuria [29]. In the
present study there was a negative correlation between
the serum sTWEAK level, and microalbuminuria level,
proteinuria level, LVMI, and mean 24-h SBP, which
might have been due to high level of Fn14 that bound tosTWEAK and decrease in the serum sTWEAK level
following chronic inflammation.
IL-17A is a cytokine that is suggested to play a role in
the pathophysiology of HT, and its relationship to HT
has been the subject of recent research. Several recent
studies have reported that the IL-17A level increases in
cases of atherosclerosis and vascular inflammation, and
that such increases contribute to progression of inflam-
mation [14,30].
Nguyen et al. reported that SBP increased significantly
in mice that received IL-17A (IP injection of 1 μg/d for
7 d), which was attributed to a decrease in the response
to aortic nitric oxide (NO)-dependent relaxation and an
increase in NO synthase Thr495 phosphorylation (which
leads to a decrease in NO production and vasodilation,
and is associated with HT) [5].
Madhur et al. [31] conducted a prospective study that
included 112 HT patients, and reported that the IL-17
level was significantly higher in the HT patients than in
the normotensive group. They suggested that the finding
was due to an increase in the level of Th17 in T cells
and an increase in the IL-17 level following infusion of
chronic angiotensin II, an increase in superoxide radicals
due to deposition of IL-17 on vessel walls, a decrease in
endothelium-related vasodilatation, and some affected
genes (e.g. stanniocalcin-1), which caused HT and vascu-
lar inflammation. In addition, they also reported that IL-
Ates et al. BMC Nephrology 2014, 15:159 Page 8 of 9
http://www.biomedcentral.com/1471-2369/15/15917 cell infiltration in the aorta occured in cases of angio-
tensin II-induced HT and that HT was not maintained
in IL-17 knockout mice.
Liu et al. [32] observed a positive correlation between
the IL-17A level and CIMT in atherosclerotic patients.
In the present study the serum IL-17A level was signifi-
cantly higher in HT patients with AOD than in those
without AOD. In addition, there was a positive correl-
ation between the serum IL-17A level and the microal-
buminuria level, proteinuria level, CIMT, LVMI, and
mean 24-h SBP, all of which are indicators of AOD. A
decrease in NO related to IL-17A may lead to endothe-
lial dysfunction that can result in atherosclerosis and an
increase in CIMT, as reported by Madhur and Nguyen.
A study that investigated the sTWEAK level as a pre-
dictor of target organ damage in HT patients reported
that a low sTWEAK level was an independent risk factor
for cardiovascular events [33]; however, findings con-
cerning the predictive value of the IL-17A level are
inconsistent.
The literature includes studies that have investigated
the relationship between a variety of biomarkers and
AOD in patients with HT [34-36]. Morillas et al. [34] re-
ported that risk factors in HT patients, including age,
smoking, diabetes mellitus, waist circumference, IL-6,
and sTNF-R1 (marker of inflammation and apoptosis),
are independent predictors of target organ damage based
on multivariate logistic regression analysis. Ratto et al.
[35] reported that the hs-CRP level was an independent
predictor of AOD, based on multivariate logistic regres-
sion analysis, and Çalışkan et al. [36] observed that the
serum uric acid level was a good predictor of coronary
flow reserve based on ROC curve analysis (AUC = 0.760,
P < 0.0001). In the present study the sTWEAK level was
observed to be a better predictor of AOD than the other
predictors (e.g. age and SBP) (AUC = 0.706, P < 0.001).
The present findings show that patient age, sTWEAK,
and mean 24-h SBP were independent predictors of
AOD, based on a multivariate model of risk factors (age,
sTWEAK level, IL-17A level, mean 24-h SBP and 24-h
DBP, and duration of HT) that independently play a role
in target organ damage. Mean age of the present study’s
HT patients with AOD was significantly higher than of
those without AOD, and there was a weak negative
correlation between the serum sTWEAK level and
patient age; however, regression analysis with inclusion
of age showed that the relationship between the serum
sTWEAK level and AOD was independent of age. To
the best of our knowledge the present study is the first to
report on the relationship between the serum sTWEAK
level and age. The only limitation of the present study is
its cross-sectional design, which precludes any conclusion
regarding the causal relationship between the serum
sTWEAK and IL17-A levels, and AOD in HT patients.Conclusion
As AOD is an interim stage in the progression of vascu-
lar diseases and is a pathology with an important role in
identifying cardiovascular risk in HT patients, AOD in
HT patients must be carefully examined. Additional pro-
spective observational studies are needed to more clearly
delineate the role of sTWEAK and IL-17A in the devel-
opment of target organ damage.
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